Das P, et al. - Between February 1, 2012, and May 31, 2016, researchers analyzed 143 candidates to examine the efficacy of enzalutamide (ENZ) to abiraterone acetate plus prednisone/prednisolone (AA+P) in subjects with metastatic castration-resistant prostate cancer (mCRPC). They observed a significantly lower chance of biochemical progression among ENZ cases as compared to AA+P subjects when adjusting for all covariates in the Cox PH model. They noticed fatigue in 38% of ENZ patients as compared to 16% of candidates with AA+P. Candidates with AA+P were recorded with slightly more hypertension as compared to in ENZ patients. No significant differences in radiographic progression-free survival or overall survival were noted but observed in biochemical progression-free survival, favoring ENZ.